行情

RIGL

RIGL

里格尔制药
NASDAQ

实时行情|Nasdaq Last Sale

1.690
-0.020
-1.17%
盘后: 1.660 -0.03 -1.78% 17:33 09/20 EDT
开盘
1.700
昨收
1.710
最高
1.730
最低
1.655
成交量
675.48万
成交额
--
52周最高
3.570
52周最低
1.600
市值
2.83亿
市盈率(TTM)
-4.8025
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RIGL 新闻

  • Should You Be Concerned About Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Historical Volatility?
  • Simply Wall St..2天前
  • Stocks That Fell to 3-Year Lows in the Week of Sept. 13
  • GuruFocus.com.09/15 20:28
  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.09/04 15:39
  • The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
  • Benzinga.09/04 11:08

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

RIGL 简况

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
展开

Webull提供Rigel Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。